New Radiotracer Improves Differential Diagnosis of Parkinson’s Disease
By MedImaging International staff writers Posted on 11 Mar 2020 |
Image: Dr. Rodrigo Teodoro and Dr. Thu Hang Lai running an automated [18F]FLUDA synthesis module (Photo courtesy of HZDR)
A new study highlights a novel positron emission tomography (PET) radionuclide that can improve image-based differential diagnostics of Parkinson's disease (PD).
Developed at Helmholtz-Zentrum Dresden-Rossendorf (HZDR; Dresden, Germany), the metabolically stable radiotracer, called [18F]FLUDA, attaches itself to adenosine (A2B) receptors in the brain and can be detected there. Metabolism studies in mice revealed that the radiometabolite can penetrate the blood-brain barrier (BBB). It also performed well in dosimetry and radiation protection studies, carried out in cooperation with the Clinic of Nuclear Medicine at the University of Leipzig (Germany), as well as in a toxicity study.
When adenosine attaches to certain receptors, it causes the nerve cells to work more slowly, including those that are significant for PD. The areas of the brain where increased radioactivity is detected must therefore have a particularly high number of receptors, which can be imaged using super-sensitive PET imaging. The study, by an interdisciplinary team from the HZDR Institute of Radiopharmaceutical Cancer Research, won the HZDR third Innovation Contest. The researchers are now preparing for clinical studies to test whether the new substance also proves its value in everyday medical practice.
“No objective criteria for the differential diagnosis of Parkinson’s disease previously existed to detect at early stage whether a patient is sensitive to the side effects, meaning that it was also impossible to develop personalized therapies,” said lead researcher Thu Hang Lai, PhD. “The new radiopharmaceutical means a great benefit for the patients, but can also reduce the treatment costs of health insurance companies.”
18F is a fluorine radioisotope that decays by positron emission 97% of the time, and electron capture 3% of the time; both modes of decay yield stable oxygen-18 (18O). 18F is an important radioisotope as a result of both its short half-life and the emission of positrons when decaying. It is primarily synthesized into fluorodeoxyglucose (FDG) for use in PET scans.
Related Links:
Helmholtz-Zentrum Dresden-Rossendorf
University of Leipzig
Developed at Helmholtz-Zentrum Dresden-Rossendorf (HZDR; Dresden, Germany), the metabolically stable radiotracer, called [18F]FLUDA, attaches itself to adenosine (A2B) receptors in the brain and can be detected there. Metabolism studies in mice revealed that the radiometabolite can penetrate the blood-brain barrier (BBB). It also performed well in dosimetry and radiation protection studies, carried out in cooperation with the Clinic of Nuclear Medicine at the University of Leipzig (Germany), as well as in a toxicity study.
When adenosine attaches to certain receptors, it causes the nerve cells to work more slowly, including those that are significant for PD. The areas of the brain where increased radioactivity is detected must therefore have a particularly high number of receptors, which can be imaged using super-sensitive PET imaging. The study, by an interdisciplinary team from the HZDR Institute of Radiopharmaceutical Cancer Research, won the HZDR third Innovation Contest. The researchers are now preparing for clinical studies to test whether the new substance also proves its value in everyday medical practice.
“No objective criteria for the differential diagnosis of Parkinson’s disease previously existed to detect at early stage whether a patient is sensitive to the side effects, meaning that it was also impossible to develop personalized therapies,” said lead researcher Thu Hang Lai, PhD. “The new radiopharmaceutical means a great benefit for the patients, but can also reduce the treatment costs of health insurance companies.”
18F is a fluorine radioisotope that decays by positron emission 97% of the time, and electron capture 3% of the time; both modes of decay yield stable oxygen-18 (18O). 18F is an important radioisotope as a result of both its short half-life and the emission of positrons when decaying. It is primarily synthesized into fluorodeoxyglucose (FDG) for use in PET scans.
Related Links:
Helmholtz-Zentrum Dresden-Rossendorf
University of Leipzig
Latest General/Advanced Imaging News
- PET Scans Reveal Hidden Inflammation in Multiple Sclerosis Patients
- Artificial Intelligence Evaluates Cardiovascular Risk from CT Scans
- New AI Method Captures Uncertainty in Medical Images
- CT Coronary Angiography Reduces Need for Invasive Tests to Diagnose Coronary Artery Disease
- Novel Blood Test Could Reduce Need for PET Imaging of Patients with Alzheimer’s
- CT-Based Deep Learning Algorithm Accurately Differentiates Benign From Malignant Vertebral Fractures
- Minimally Invasive Procedure Could Help Patients Avoid Thyroid Surgery
- Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery
- AR Application Turns Medical Scans Into Holograms for Assistance in Surgical Planning
- Imaging Technology Provides Ground-Breaking New Approach for Diagnosing and Treating Bowel Cancer
- CT Coronary Calcium Scoring Predicts Heart Attacks and Strokes
- AI Model Detects 90% of Lymphatic Cancer Cases from PET and CT Images
- Breakthrough Technology Revolutionizes Breast Imaging
- State-Of-The-Art System Enhances Accuracy of Image-Guided Diagnostic and Interventional Procedures
- Catheter-Based Device with New Cardiovascular Imaging Approach Offers Unprecedented View of Dangerous Plaques
- AI Model Draws Maps to Accurately Identify Tumors and Diseases in Medical Images